By Sahil Pandey and Puyaan Singh Feb 27 (Reuters) - The U.S. Food and Drug Administration on Friday approved Ascendis Pharma's once-weekly therapy for children with a rare genetic disorder that causes ...

The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing ...

The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing intervalCommercial availability expected during early part of Q2 2026Rare Pedia ...

Love, Parenthood, and the Courage to Choose People are curious. Sometimes harmlessly so. Other times… not so much. The ...

Shares in BridgeBio were ticking up today after it revealed data from its phase 3 trial of infigratinib in achondroplasia, ...

Find latest healthcare news from every corner of the globe at Reuters.com, your online source for breaking international news ...

Nigerian actor, Victor Udochukwu Nwaogu, popularly known as Nkubi, has revealed that one of the reasons he became an actor ...

Nkechi Vivian, wife of popular content creator Nwaogu Udochukwu, popularly known as Nkubi, has revealed a shocking encounter with a medical professional regarding her pregnancy. In an interview on ...

Ascendis Pharma secured Food and Drug Administration approval under the agency's accelerated approval program for Yuviwel, a treatment for the genetic condition that causes dwarfism.

BridgeBio Pharma (BBIO) stock jumps as a Phase 3 trial for the company's achondroplasia therapy succeeds. Read more here.

"Not only is it a community of people that you're able to hang out with and play with and be a team with, but it helps your improve your quality of life." ...